The Blue Box Biomedical Solutions — Seed · €3M

The Blue Box closed a €3M seed round led by Nordic impact fund Unconventional Ventures to advance its AI-powered, urine-based breast cancer screening test toward clinical trials and CE marking by the end of 2026. Austrian fund Fund F, Barcelona deeptech fund Grow Venture Partners, the Spanish Association Against Cancer (AECC) and mission-driven backers Hans(wo)man Group and the Foss/Krups Family also participated.